Therapies in ankylosing spondylitis—from clinical trials to clinical practice

Until recently, the therapeutic options for patients suffering from active AS comprised NSAIDs and TNF inhibitor therapy. Although these are effective in a significant proportion of patients, not all patients respond and some are intolerant to these therapies. Therefore, there is a clear unmet treat...

Descripción completa

Detalles Bibliográficos
Autor principal: Tahir, Hasan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238222/
https://www.ncbi.nlm.nih.gov/pubmed/30445480
http://dx.doi.org/10.1093/rheumatology/key152
_version_ 1783371328699498496
author Tahir, Hasan
author_facet Tahir, Hasan
author_sort Tahir, Hasan
collection PubMed
description Until recently, the therapeutic options for patients suffering from active AS comprised NSAIDs and TNF inhibitor therapy. Although these are effective in a significant proportion of patients, not all patients respond and some are intolerant to these therapies. Therefore, there is a clear unmet treatment need in AS patients. This article reviews the evidence for targets currently being studied in AS. This includes the IL-12/23 inhibitor ustekinumab, the pan-Janus kinase inhibitor tofacitinib and the anti-IL-17A antibody secukinumab.
format Online
Article
Text
id pubmed-6238222
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62382222018-11-21 Therapies in ankylosing spondylitis—from clinical trials to clinical practice Tahir, Hasan Rheumatology (Oxford) Reviews Until recently, the therapeutic options for patients suffering from active AS comprised NSAIDs and TNF inhibitor therapy. Although these are effective in a significant proportion of patients, not all patients respond and some are intolerant to these therapies. Therefore, there is a clear unmet treatment need in AS patients. This article reviews the evidence for targets currently being studied in AS. This includes the IL-12/23 inhibitor ustekinumab, the pan-Janus kinase inhibitor tofacitinib and the anti-IL-17A antibody secukinumab. Oxford University Press 2018-11 2018-11-16 /pmc/articles/PMC6238222/ /pubmed/30445480 http://dx.doi.org/10.1093/rheumatology/key152 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reviews
Tahir, Hasan
Therapies in ankylosing spondylitis—from clinical trials to clinical practice
title Therapies in ankylosing spondylitis—from clinical trials to clinical practice
title_full Therapies in ankylosing spondylitis—from clinical trials to clinical practice
title_fullStr Therapies in ankylosing spondylitis—from clinical trials to clinical practice
title_full_unstemmed Therapies in ankylosing spondylitis—from clinical trials to clinical practice
title_short Therapies in ankylosing spondylitis—from clinical trials to clinical practice
title_sort therapies in ankylosing spondylitis—from clinical trials to clinical practice
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238222/
https://www.ncbi.nlm.nih.gov/pubmed/30445480
http://dx.doi.org/10.1093/rheumatology/key152
work_keys_str_mv AT tahirhasan therapiesinankylosingspondylitisfromclinicaltrialstoclinicalpractice

Ejemplares similares